Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.37 |
| ▸ | LAP3 | P28838 | 3/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1537346 | 0.88 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| SCHEMBL1537226 | 0.88 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Serine SCHEMBL6666261 | 0.85 | SLC7A5 (0.38) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Serine SCHEMBL5320795 | 0.83 | SLC7A5 (0.39) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Serine SCHEMBL1064689 | 0.81 | SLC1A1 (0.43) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Serine SCHEMBL418634 | 0.81 | PTGS1 (0.48) | SLC1A1GRIK1GRIK2 | |
| Serine SCHEMBL3961258 | 0.81 | SLC1A5 (0.36) | SLC1A1GRIK1GRIK2 | |
| SCHEMBL16972731 | 0.80 | SLC7A5 (0.64) | SLC7A5SLC1A3SLC1A2SLC1A1RNPEP | |
| Leucine SCHEMBL348968 | 0.80 | SLC7A5 (0.69) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Leucine SCHEMBL27569034 | 0.80 | SLC7A5 (0.69) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601330-A4 | ANTITUMOR AGENTS COMPRISING A TARGETING PORTION AND AN IMMUNE RESPONSE TRIGGERING PORTION | GHC RES DEV CORP (US) | 2008-05-07 | — | — | EP | claimed |
| CN-1787838-A | Antitumor agent comprising targeting moiety and immune response triggering moiety | GREENVILLE HOSPITAL SYSTEM (US) | 2006-06-14 | — | — | CN | claimed |
| EP-1601330-A2 | ANTITUMOR AGENTS COMPRISING A TARGETING PORTION AND AN IMMUNE RESPONSE TRIGGERING PORTION | Greenville Hospital System (US) | 2005-12-07 | — | — | EP | claimed |
| US-20050025771-A1 | Antitumor agents comprising a targeting portion and an immune response triggering portion | GREENVILLE HOSPITAL SYSTEM | 2005-02-03 | — | — | US | claimed |
| WO-2004078137-A2 | ANTITUMOR AGENTS COMPRISING A TARGETING PORTION AND AN IMMUNE RESPONSE TRIGGERING PORTION | GREENVILLE HOSPITAL SYSTEM (US) | 2004-09-16 | — | — | WO | claimed |
| US-20230165952-A1 | BETACORONAVIRUS PROPHYLAXIS AND THERAPY | Nykode Therapeutics ASA (NO) | 2023-06-01 | — | — | US | disclosed |
| EP-4143210-A1 | BETACORONAVIRUS PROPHYLAXIS AND THERAPY | Nykode Therapeutics ASA (NO) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021219897-A1 | BETACORONAVIRUS PROPHYLAXIS AND THERAPY | VACCIBODY AS (NO) | 2021-11-04 | — | — | WO | disclosed |
| CN-106083932-B | Novel preactivated oxazaphosphorin derivative, application and preparation method | 法国古士塔柏罗斯学院 | 2019-08-06 | — | — | CN | disclosed |
| US-10125157-B2 | Derivatives of oxazaphosphorines that are pre-activated, use and method of preparation | INSTITUT GUSTAVE ROUSSY (FR) | 2018-11-13 | — | — | US | disclosed |
| EP-2649084-B1 | NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION | ROUSSY INST GUSTAVE (FR) | 2017-02-22 | — | — | EP | disclosed |
| US-20160333038-A1 | NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION | INSTITUT GUSTAVE ROUSSY (FR) | 2016-11-17 | — | — | US | disclosed |
| WO-2001053342-A1 | CHIMERIC PROSTATE-HOMING PEPTIDES WITH PRO-APOPTOTIC ACTIVITY | THE BURNHAM INSTITUTE (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-1998010795-A9 | TUMOR HOMING MOLECULES, CONJUGATES DERIVED THEREFROM, AND METHODS OF USING SAME | BURNHAM INST (US) | 2001-06-21 | — | — | WO | disclosed |
| US-6180084-B1 | CONTACTING PURIFIED NGR RECEPTOR WITH ONE OR MORE MOLECULES AND DETERMINING SPECIFIC BINDING OF MOLECULE TO NGR RECEPTOR, WHERE PRESENCE OF SPECIFIC BINDING IDENTIFIES MOLECULE AS TUMOR HOMING MOLECULE THAT HOMES TO ANGIOGENIC VASCULATURE | THE BURNHAM INSTITUTE | 2001-01-30 | — | — | US | disclosed |
| WO-2000042973-A2 | HOMING PRO-APOPTOTIC CONJUGATES AND METHODS OF USING SAME | THE BURNHAM INSTITUTE (US) | 2000-07-27 | — | — | WO | disclosed |
| EP-1015884-A1 | METHODS OF IDENTIFYING MOLECULES THAT HOME TO ANGIOGENIC VASCULATURE IN TUMORS | The Burnham Institute (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0927045-A2 | TUMOR HOMING MOLECULES, CONJUGATES DERIVED THEREFROM, AND METHODS OF USING SAME | The Burnham Institute (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1999013329-A1 | METHODS OF IDENTIFYING MOLECULES THAT HOME TO ANGIOGENIC VASCULATURE IN TUMORS | THE BURNHAM INSTITUTE (US) | 1999-03-18 | — | — | WO | disclosed |
| WO-1998010795-A2 | TUMOR HOMING MOLECULES, CONJUGATES DERIVED THEREFROM, AND METHODS OF USING SAME | THE BURNHAM INSTITUTE (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333038-A1 | NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION | INPP5B, TYMP, ENTPD5 | SLC7A5 3946/4885SLC1A3 3877/4885SLC1A2 4168/4885 |
| US-10125157-B2 | Derivatives of oxazaphosphorines that are pre-activated, use and method of preparation | TYMP, INPP5B, ENTPD5 | SLC7A5 3637/4885SLC1A3 3459/4885SLC1A2 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.